HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform. This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by ...

August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the enrolment of the first two patients by the Pan American Center for Onc ...

Core Viewpoint - Energi Holdings Limited will acquire a 51% stake in Tembo e-LV B.V. from VivoPower International PLC, enabling Tembo to proceed with its SPAC merger at an equity valuation of $838 million [1][2]. Group 1: Investment Details - The total enterprise valuation for 100% of Tembo is set at $200 million, with the equity purchase price for the 51% stake adjusted for Tembo's net debt and customary adjustments at closing [2]. - The investment is contingent upon the completion of Tembo's business combination agreement with Cactus Acquisition Corp 1 Limited and customary closing conditions [2]. Group 2: Corporate Structure and Strategy - VivoPower has initiated the recruitment of a dedicated board of directors for Tembo in preparation for its public listing [3]. - VivoPower is undergoing a strategic transformation to focus on XRP and digital assets, aiming to support decentralized finance infrastructure and blockchain applications [4]. Group 3: Company and Subsidiary Overview - VivoPower operates globally with a focus on sustainable energy solutions and has two business units: Tembo and Caret Digital [5]. - Tembo specializes in battery-electric and off-road vehicle solutions for various industrial sectors, including mining and agriculture, providing electrification solutions for utility vehicle fleet owners [6].

MONROE TOWNSHIP, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative, low-carbon offshore power, data, and service solutions, today announced the opening of a new office at the Association for Uncrewed Vehicle Systems International (AUVSI) headquarters in Washington, D.C. This strategic move marks a significant milestone in the Company’s expansion efforts and underscores its commitment to advancing uncrewed systems ope ...

Core Insights - NRx Pharmaceuticals has received an expanded Fast Track Designation from the FDA for NRX-100, allowing it to address an unmet medical need for treating suicidal depression in over 13 million Americans annually, significantly increasing its market potential [4][11][7] - The company is advancing its drug development pipeline, including NRX-100 and NRX-101, with various regulatory filings and applications aimed at accelerating approval processes [8][15][28] - HOPE Therapeutics, a subsidiary of NRx, is establishing a network of interventional psychiatry clinics to provide comprehensive care for mental health conditions, aiming to address a significant public health crisis [20][18][19] Drug Development and Regulatory Activities - NRX-100 is being developed through two paths: a generic approval via an Abbreviated New Drug Application (ANDA) and an innovative drug path via a New Drug Application (NDA) [8][28] - The ANDA market for ketamine is estimated at $750 million, with expectations to enter this market in early 2026 [8] - NRX-101 has received Breakthrough Therapy Designation and is being prepared for a New Drug Application, with over 80,000 pages of supporting material submitted [15][16] Financial Overview - For Q2 2025, the company reported a net loss of $17.6 million, compared to a net loss of $7.9 million in Q2 2024, primarily due to non-cash fair value accounting measurements [24] - The company had approximately $2.9 million in cash and cash equivalents as of June 30, 2025, which is expected to support operations into 2026 [25] HOPE Therapeutics and Market Strategy - HOPE Therapeutics aims to create a national network of clinics to provide integrated care for patients with suicidal depression and related conditions, addressing fragmented mental health treatment [20][18] - The company is negotiating to acquire additional facilities, targeting $100 million in total forward pro-forma revenue by the end of 2025 [23] Toxicology and Safety Considerations - A Citizen's Petition has been filed to remove Benzethonium Chloride from intravenous ketamine products, citing safety concerns and lack of GRAS status [9][10] - The proprietary formulation of NRX-100 is preservative-free, which is expected to be well-received by both physicians and patients, potentially capturing a larger market share [10][9]

Core Insights - The AVALON study published in the American Journal of Managed Care reinforces the clinical superiority of iRhythm Technologies' Zio long-term continuous monitoring (LTCM) service among commercially insured patients, demonstrating its effectiveness compared to other ambulatory cardiac monitoring (ACM) modalities [1][2][3] Study Findings - AVALON is the largest real-world study of its kind, involving 428,707 commercially insured patients, and shows that the Zio LTCM service has the highest diagnostic yield, fastest time to diagnosis, and lowest total healthcare costs compared to other monitoring modalities [4][6][11] - The Zio LTCM service was associated with a 2.04 times higher likelihood of new arrhythmia diagnosis within 90 days compared to Holter monitors, and 1.69 times compared to ambulatory event monitors (AEM) [8][12] - The median time from end-of-wear to arrhythmia diagnosis for the Zio LTCM service was 9 days, significantly faster than Holter (12 days) and AEM (30 days) [12] - The Zio LTCM service demonstrated the lowest total medical and pharmacy costs at $10,476 per patient-year, compared to Holter ($11,042), AEM ($11,492), and non-iRhythm LTCM services ($11,293) [12] Clinical Implications - The findings indicate that the Zio LTCM service leads to lower healthcare resource utilization, including fewer emergency department visits and hospitalizations, and a lower likelihood of cardiovascular events [11][12] - The study confirms that the Zio LTCM service's advantages extend across diverse patient populations and payer segments, building on previous findings from the Medicare-focused CAMELOT study [6][13] Company Commitment - iRhythm Technologies emphasizes its commitment to delivering clinically meaningful innovations that drive value across the healthcare system, as highlighted by the results of the AVALON study [3][10][14]

Core Viewpoint - American Rare Earths has initiated construction of a test mine at the Cowboy State Mine, marking a significant step in the development of the Halleck Creek deposit in Wyoming [1][10]. Group 1: Test Mining Program - The test mining program aims to extract approximately 3,200 tonnes of ore to serve as feedstock for a demonstration plant and support mineral processing optimization [2][4]. - The first blast has been successfully executed, fracturing weathered material to a depth of about 3.6 meters, which will be excavated and stockpiled [3][5]. Group 2: Importance of Test Mining - The test mining work will provide essential mining-related data, including drill penetration rates and blast fragmentation, which are crucial for mine design [4][7]. - The commencement of test mining is a critical milestone, as it will validate processing flowsheets, generate end-product samples, and support future technical studies [4][6]. Group 3: Strategic Goals - The demonstration plant will facilitate metallurgical testing, process optimization, and the production of samples for potential offtake partners [6][7]. - The project aims to de-risk full-scale development by proving processing performance at scale and refining engineering and cost models for future plant construction [7][10]. Group 4: Industry Context - American Rare Earths is positioned to reduce U.S. reliance on rare earth imports, primarily from China, while addressing the growing demand for these critical minerals [11][12]. - The Halleck Creek Project is significant for U.S. supply chain security and is committed to environmentally responsible mining practices [12].

Core Insights - FTC Solar, Inc. is actively engaging with investors through multiple upcoming conferences and events, indicating a focus on investor relations and market presence [1][2]. Company Overview - FTC Solar, founded in 2017, specializes in solar tracker systems, technology, software, and engineering services, aimed at enhancing energy production in solar installations [4]. - The company's solar trackers optimize panel orientation to the sun, significantly increasing energy output and offering a competitive installation cost-per-watt advantage [4]. Upcoming Events - The company will participate in the H.C. Wainwright Global Investment Conference on September 8, 2025, hosting virtual investor meetings [1]. - FTC Solar will also be present at the Roth Solar & Storage Symposium and RE+ 2025 in Las Vegas on September 9-10, 2025, conducting in-person and group investor meetings [2]. - Interested parties are encouraged to visit FTC Solar's booth V7655 at the events to learn more about their innovative solutions [3].

Core Insights - Enlivex Therapeutics announced positive topline data from the Phase IIa trial of Allocetra™, showing significant improvements in knee pain and function in patients with moderate-to-severe knee osteoarthritis [1][2][3] Group 1: Clinical Trial Results - In the modified intention-to-treat population, Allocetra™ demonstrated a 24% reduction in knee pain and a 26% improvement in knee function compared to placebo [1] - For age-related primary osteoarthritis patients, Allocetra™ resulted in a 72% reduction in knee pain and a 95% improvement in knee function compared to placebo, indicating a substantial and statistically significant effect [1][2] Group 2: Safety Profile - The trial reported a favorable safety profile for Allocetra™, with no severe adverse events and only mild to moderate, transient, and treatable side effects observed in most patients [2] Group 3: Company Overview - Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming immunotherapy, developing Allocetra™ as a universal cell therapy aimed at reprogramming macrophages to restore immune balance [8] - The company emphasizes the significant unmet medical need in the knee osteoarthritis market, which affects over 32.5 million Americans and is projected to increase to 78 million by 2040 [6]

Kfar Saba, Israel, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announced that it has received a purchase order for its advanced Counter-Unmanned Aerial Systems (C-UAS) solution from a defense entity. This is another achievement for ParaZero in its continued expansion into the defense market and the rapidly g ...